Structure Therapeutics (NASDAQ:GPCR) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Structure Therapeutics (NASDAQ:GPCR) from a hold rating to a sell rating in a research note released on Saturday morning.

A number of other equities research analysts have also issued reports on the stock. Leerink Partners reissued an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. JPMorgan Chase & Co. raised their target price on shares of Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, January 22nd. The Goldman Sachs Group raised shares of Structure Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 20th. Guggenheim raised their target price on shares of Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Finally, William Blair reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Monday, March 16th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $109.25.

Structure Therapeutics Stock Down 2.9%

Shares of Structure Therapeutics stock opened at $38.69 on Friday. The firm has a market cap of $2.74 billion, a PE ratio of -44.47 and a beta of -1.31. Structure Therapeutics has a 12-month low of $15.80 and a 12-month high of $94.90. The company’s fifty day simple moving average is $48.84 and its two-hundred day simple moving average is $56.41.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. As a group, sell-side analysts expect that Structure Therapeutics will post -1.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of GPCR. The Manufacturers Life Insurance Company lifted its position in Structure Therapeutics by 19.1% during the 1st quarter. The Manufacturers Life Insurance Company now owns 114,814 shares of the company’s stock valued at $5,534,000 after acquiring an additional 18,427 shares during the period. Orbimed Advisors LLC lifted its position in Structure Therapeutics by 27.0% during the 1st quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock valued at $71,114,000 after acquiring an additional 313,600 shares during the period. PSquared Asset Management AG purchased a new position in Structure Therapeutics during the 1st quarter valued at about $1,687,000. Siren L.L.C. lifted its position in Structure Therapeutics by 23.2% during the 1st quarter. Siren L.L.C. now owns 1,328,698 shares of the company’s stock valued at $64,043,000 after acquiring an additional 250,000 shares during the period. Finally, Cetera Investment Advisers lifted its position in Structure Therapeutics by 17.0% during the 1st quarter. Cetera Investment Advisers now owns 7,720 shares of the company’s stock valued at $372,000 after acquiring an additional 1,124 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.